drugset / Trial / NCT01618188

A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes

NCT01618188

Phase 1 Completed 52 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic properties (the effect of the investigated drug on the body) of NN1218 in subjects with type 1 diabetes.

Timeline

Start
2012-06-11
Primary completion
2012-09-07
Completion
2012-09-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator insulin aspart Protein / enzyme biologic 0.2 iu/kg Subcutaneous